Stem cell study seeks clues to broken heart syndrome recovery
NCT ID NCT07604467
First seen Jun 02, 2026 · Last updated Jun 19, 2026 · Updated 6 times
Summary
This study looks at whether a type of stem cell (CD34+) helps the heart heal in people with Takotsubo syndrome, also known as broken heart syndrome. Researchers will measure heart function in 40 adults at the start and after 6 months. The goal is to understand the link between these cells and heart recovery, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia
RECRUITINGLjubljana, Ljubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.